{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T17:22:49Z","timestamp":1766510569835,"version":"3.48.0"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:p>This letter comments on the recent study by Mastorino et al. (Clin Exp Dermatol 2025; https:\/\/doi.org\/10.1093\/ced\/llaf305) reporting high long-term drug survival (87.2%) and effectiveness of risankizumab in real-world psoriasis treatment. We highlight a key methodological limitation, the lack of adherence assessment, which may confound interpretation of persistence outcomes. Incorporating adherence data in future studies would enhance the accuracy, interpretability and clinical relevance of real-world evidence.<\/jats:p>","DOI":"10.1093\/ced\/llaf386","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T11:33:07Z","timestamp":1755603187000},"page":"128-129","source":"Crossref","is-referenced-by-count":0,"title":["Comment on \u2018Drug survival, effectiveness and safety of risankizumab for moderate-to-severe psoriasis for up to 4 years\u2019"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0248-4208","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"Borr\u00e1s-Blasco","sequence":"first","affiliation":[{"name":"Pharmacy Department, Hospital Sagunto , Sagunto ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Valcuende-Rosique","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Alzira , Alzira ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Cornejo-Uixeda","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Sagunto , Sagunto ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"2025122312174591700_llaf386-B1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/ced\/llaf305","article-title":"Drug survival, effectiveness and safety of risankizumab for moderate-to-severe psoriasis for up to 4\u2005years","volume":"51","author":"Mastorino","year":"2026","journal-title":"Clin Exp Dermatol"},{"key":"2025122312174591700_llaf386-B2","doi-asserted-by":"crossref","first-page":"T141","DOI":"10.1016\/j.farma.2023.07.020","article-title":"Persistence, current state of the art","volume":"48","author":"Rodriguez Goicoechea","year":"2024","journal-title":"Farm Hosp"},{"key":"2025122312174591700_llaf386-B3","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/jdv.15600","article-title":"Expert consensus on the persistence of biological treatments in moderate to severe psoriasis","volume":"33","author":"De la Cueva Dobao","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025122312174591700_llaf386-B4","doi-asserted-by":"crossref","first-page":"101123","DOI":"10.1016\/j.jhqr.2025.101123","article-title":"[Influence of adherence on persistence value inside Medicina 6P.]","volume":"40","author":"Borr\u00e1s Blasco","year":"2025","journal-title":"J Healthc Qual Res"},{"key":"2025122312174591700_llaf386-B5","doi-asserted-by":"crossref","DOI":"10.1093\/intqhc\/mzae026","article-title":"Integration of persistence in the 5P-medicine approach for age-related chronic diseases","volume":"36","author":"Borr\u00e1s Blasco","year":"2024","journal-title":"Int J Qual Health Care"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf386\/64087960\/llaf386.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/1\/128\/64087960\/llaf386.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/1\/128\/64087960\/llaf386.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T17:17:55Z","timestamp":1766510275000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/1\/128\/8238403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":5,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,20]]},"published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf386","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"type":"print","value":"0307-6938"},{"type":"electronic","value":"1365-2230"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,8,20]]}}}